{
  "timeline": [
    {
      "date": "1878/3",
      "category": "会社設立",
      "region": "",
      "importance": 3,
      "event": "初代塩野義三郎が薬種問屋を創業",
      "detail": "大阪・道修町で和漢薬の販売を開始。1886〜1897年に取扱品を洋薬に転換し直接欧米商社と取引",
      "significance": "後の製薬企業塩野義の原点。和漢薬から洋薬への転換は近代日本の医薬流通の先駆け",
      "source": "有価証券報告書"
    },
    {
      "date": "1910/2",
      "category": "設備投資",
      "region": "",
      "importance": 2,
      "event": "塩野製薬所を建設",
      "detail": "問屋業から自社製造へ進出",
      "significance": "販売中心から製造へ事業基盤を転換した節目",
      "source": "有価証券報告書"
    },
    {
      "date": "1919/6",
      "category": "組織再編",
      "region": "",
      "importance": 2,
      "event": "株式会社塩野義商店に改組",
      "detail": "資本金150万円で株式会社化",
      "significance": "個人商店から近代的株式会社への転換",
      "source": "有価証券報告書",
      "amount": "資本金150万円"
    },
    {
      "date": "1922/5",
      "category": "設備投資",
      "region": "",
      "importance": 1,
      "event": "杭瀬工場を取得",
      "detail": "神戸醋酸工業の土地・建物を買収して発足",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "1943/7",
      "category": "組織再編",
      "region": "",
      "importance": 2,
      "event": "塩野義製薬株式会社に改称",
      "detail": "戦時下で社名を製薬専業として明確化",
      "significance": "現社名の確立。製薬専業企業としてのアイデンティティ確定",
      "source": "有価証券報告書"
    },
    {
      "date": "1945/8",
      "category": "組織再編",
      "region": "",
      "importance": 1,
      "event": "塩野義化学を合併",
      "detail": "赤穂工場として発足",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "1946/1",
      "category": "設備投資",
      "region": "",
      "importance": 1,
      "event": "油日農場を開設",
      "detail": "滋賀県に薬用植物研究の拠点",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "1949/5",
      "category": "株式上場",
      "region": "",
      "importance": 3,
      "event": "東京・大阪両証券取引所に株式上場",
      "detail": "",
      "significance": "戦後復興期の上場により公的資本市場に参加。長期成長への基盤整備",
      "source": "有価証券報告書"
    },
    {
      "date": "1963/12",
      "category": "",
      "region": "中国",
      "importance": 1,
      "event": "台湾塩野義製薬を設立",
      "detail": "初の海外子会社",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "1968/3",
      "category": "設備投資",
      "region": "",
      "importance": 1,
      "event": "摂津工場を建設",
      "detail": "",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "1976/8",
      "category": "",
      "region": "",
      "importance": 1,
      "event": "日亜薬品工業を設立",
      "detail": "後のシオノギファーマ",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "1983/3",
      "category": "設備投資",
      "region": "",
      "importance": 1,
      "event": "金ケ崎工場を建設",
      "detail": "岩手県に新工場",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "1998/8",
      "category": "",
      "region": "",
      "importance": 1,
      "event": "武州製薬を設立",
      "detail": "",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "1999/4",
      "category": "社長交代",
      "region": "",
      "importance": 2,
      "event": "塩野元三が社長に就任",
      "detail": "創業家出身の社長",
      "significance": "創業家による経営継続。後の研究開発出身者への交代に向けた橋渡し期",
      "source": ""
    },
    {
      "date": "2001/2",
      "category": "",
      "region": "米州",
      "importance": 2,
      "event": "シオノギUSAを設立",
      "detail": "米国に直接的な拠点を構築",
      "significance": "本格的なグローバル展開への足掛かり",
      "source": "有価証券報告書"
    },
    {
      "date": "2008/4",
      "category": "社長交代",
      "region": "",
      "importance": 3,
      "event": "手代木功が社長に就任",
      "detail": "塩野元三の後任。研究開発出身",
      "significance": "創業家経営から研究開発出身者経営への転換。感染症領域への選択と集中の起点",
      "source": ""
    },
    {
      "date": "2008/10",
      "category": "企業買収",
      "region": "米州",
      "importance": 3,
      "event": "米サイエルファーマを買収",
      "detail": "後にシオノギファーマINCに商号変更。米国における自社販売拠点獲得",
      "significance": "米国市場での自社販売体制を構築する転機。後のViiV事業の基盤となった",
      "source": "有価証券報告書"
    },
    {
      "date": "2010/3",
      "category": "事業売却",
      "region": "",
      "importance": 1,
      "event": "武州製薬の全株式を譲渡",
      "detail": "",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2010/10",
      "category": "",
      "region": "",
      "importance": 1,
      "event": "シオノギテクノアドバンスリサーチを設立",
      "detail": "",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2011/4",
      "category": "組織再編",
      "region": "米州",
      "importance": 1,
      "event": "Shionogi Inc.が米2社を吸収合併",
      "detail": "シオノギUSAおよびシオノギファーマINCを統合",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2011/7",
      "category": "設備投資",
      "region": "",
      "importance": 2,
      "event": "医薬研究センターを建設",
      "detail": "大阪府に創薬研究機能を集約",
      "significance": "研究開発体制を一拠点に集約。感染症特化戦略の物理的基盤",
      "source": "有価証券報告書"
    },
    {
      "date": "2011/10",
      "category": "企業買収",
      "region": "中国",
      "importance": 1,
      "event": "中国C&Oファーマシューティカルを買収",
      "detail": "",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2012/2",
      "category": "",
      "region": "",
      "importance": 1,
      "event": "シオノギLtd.を設立",
      "detail": "後のShionogi B.V.",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2013/3",
      "category": "",
      "region": "中国",
      "importance": 1,
      "event": "北京塩野義医薬科技を設立",
      "detail": "",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2016/1",
      "category": "",
      "region": "",
      "importance": 2,
      "event": "シオノギヘルスケアを設立",
      "detail": "",
      "significance": "コンシューマーヘルスケア事業の分社化。医療用医薬品とOTCの事業分離",
      "source": "有価証券報告書"
    },
    {
      "date": "2016/4",
      "category": "組織再編",
      "region": "",
      "importance": 1,
      "event": "シオノギヘルスケアにOTC事業を承継",
      "detail": "",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2018/10",
      "category": "",
      "region": "",
      "importance": 2,
      "event": "シオノギファーマを設立",
      "detail": "医療用医薬品の製造機能を集約する受け皿",
      "significance": "医薬品製造機能を分社化し外部受託も視野に入れた製造体制を構築",
      "source": "有価証券報告書"
    },
    {
      "date": "2018/11",
      "category": "",
      "region": "欧州",
      "importance": 1,
      "event": "Shionogi B.V.をオランダに設立",
      "detail": "欧州統括拠点",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2019/4",
      "category": "組織再編",
      "region": "",
      "importance": 1,
      "event": "シオノギファーマに医療用医薬品の製造を承継",
      "detail": "複数の製造子会社をシオノギファーマに統合",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2019/10",
      "category": "",
      "region": "",
      "importance": 1,
      "event": "エムスリーとストリーム・アイを合弁設立",
      "detail": "デジタルヘルス領域",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2019/12",
      "category": "企業買収",
      "region": "",
      "importance": 1,
      "event": "UMNファーマを買収",
      "detail": "ワクチン開発企業",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2020/5",
      "category": "企業買収",
      "region": "",
      "importance": 1,
      "event": "米Tetra Therapeuticsを買収",
      "detail": "中枢神経系の創薬企業",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2020/8",
      "category": "",
      "region": "中国",
      "importance": 1,
      "event": "平安塩野義（香港）を設立",
      "detail": "平安保険との合弁",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2020/10",
      "category": "企業買収",
      "region": "",
      "importance": 1,
      "event": "シオノギファーマがナガセ医薬品を買収",
      "detail": "",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2020/11",
      "category": "",
      "region": "中国",
      "importance": 2,
      "event": "平安塩野義（中国）を設立",
      "detail": "平安保険との合弁で中国市場参入",
      "significance": "中国市場への本格進出。後にジェネリックから新薬中心へ転換",
      "source": "有価証券報告書"
    },
    {
      "date": "2021/11",
      "category": "",
      "region": "",
      "importance": 1,
      "event": "Pharmiraを設立",
      "detail": "治験薬製造",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2022/4",
      "category": "組織再編",
      "region": "",
      "importance": 1,
      "event": "東証プライム市場に移行",
      "detail": "東証市場区分見直し",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2022/4",
      "category": "組織再編",
      "region": "",
      "importance": 1,
      "event": "シオノギファーマがナガセ医薬品を吸収合併",
      "detail": "",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2022/4",
      "category": "組織再編",
      "region": "",
      "importance": 2,
      "event": "Pharmiraに治験薬製造事業の一部を承継",
      "detail": "シオノギファーマから分社",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2022/6",
      "category": "社長交代",
      "region": "",
      "importance": 2,
      "event": "手代木功が代表取締役会長兼社長CEOに就任",
      "detail": "会長兼任で経営体制を強化",
      "significance": "長期政権下での経営権限集中。ゾコーバ事業化の重要局面に対応する体制",
      "source": "有価証券報告書"
    },
    {
      "date": "2022/11",
      "category": "",
      "region": "",
      "importance": 4,
      "event": "新型コロナ治療薬ゾコーバが緊急承認",
      "detail": "国産初の経口COVID-19治療薬として緊急承認制度に基づき承認",
      "significance": "日本初の経口COVID-19治療薬。国産創薬の存在感を国際的に示した転機。22年度業績の大幅増益要因",
      "source": "IR"
    },
    {
      "date": "2023/7",
      "category": "企業買収",
      "region": "",
      "importance": 3,
      "event": "米Qpex Biopharmaを買収",
      "detail": "抗菌薬開発企業。セフィデロコル後継パイプライン獲得",
      "significance": "感染症領域への選択と集中を加速。塩野義の戦略的M&Aの典型",
      "source": "有価証券報告書"
    },
    {
      "date": "2023/7",
      "category": "組織再編",
      "region": "",
      "importance": 1,
      "event": "シオノギビジネスパートナー株式の一部売却",
      "detail": "持分法適用関連会社化",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2023/10",
      "category": "",
      "region": "",
      "importance": 1,
      "event": "Shionogi-Apnimed Sleep Science設立",
      "detail": "睡眠障害領域の合弁",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2024/4",
      "category": "組織再編",
      "region": "",
      "importance": 1,
      "event": "シオノギファーマがPharmiraを吸収合併",
      "detail": "",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2025/1",
      "category": "企業買収",
      "region": "中国",
      "importance": 1,
      "event": "平安塩野義（香港）を完全子会社化",
      "detail": "",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2025/3",
      "category": "企業買収",
      "region": "中国",
      "importance": 2,
      "event": "平安塩野義（中国）を完全子会社化",
      "detail": "平安保険との合弁を解消し単独子会社化",
      "significance": "中国事業の自主運営体制への転換。新薬モデルへの集中を加速",
      "source": "有価証券報告書"
    }
  ]
}